17 Jun 2020
United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 17, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation...
05 Jun 2020
United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., June 5, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. District Court for the District...
26 May 2020
United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United...
06 May 2020
United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United...
- First quarter Orenitram® net revenue growth of 18% year-over-year
- Major milestones such as the INCREASE filing and Remunity™ Pump launch remain on track despite the COVID-19 pandemic
- United...
- Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences
- Separately, total...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 22, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2020 financial results before the...
26 Feb 2020
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results
~ Full year net revenue growth of 3% excluding Adcirca® ~
~ Company expects 2020 full year net revenue growth ~
~ INCREASE study of Tyvaso® in PH-ILD meets primary and secondary endpoints
~~ Remunity™...
25 Feb 2020
United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United...
~ Remunity™ expected to be available for patients by July 2020
RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research &...
24 Feb 2020
United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
~ First pivotal clinical trial to demonstrate a benefit in PH-ILD ~
~ NDA supplement to be filed by mid-year
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2019 financial...